99tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer

Nuclear Medicine Communications

Volumn 20, Issue 2, 1999, Pages 115-122

  Muzzammil, T ^a,b   Ballinger, J R ^a,b   Moore, M J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ELACRIDAR; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; UNCLASSIFIED DRUG; VALSPODAR; ACRIDINE DERIVATIVE; CYCLOSPORIN DERIVATIVE; DIAGNOSTIC AGENT; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; RADIOISOTOPE DISTRIBUTION; SCINTISCANNING; TISSUE DISTRIBUTION; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG ANTAGONISM; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; METABOLISM; MOUSE MUTANT; SENSITIVITY AND SPECIFICITY; XENOGRAFT;

ACRIDINES; ANIMALS; BREAST NEOPLASMS; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ISOQUINOLINES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TETRAHYDROISOQUINOLINES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032589211     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-199902000-00002     Document Type: Article

References (33)

1. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316: 1388-1393.
2. Ford JM. Modulators of multidrug resistance: Preclinical studies. Hematol Oncol Clin N Am 1995; 9: 337-361.
3. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer 1993; 72: 3553-3563.
4. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
5. Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I. 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast cancer cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995; 16: 253-257.
6. Duran-Cordobes M, Starzec A, Delmon-Moingeon L et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression. J Nucl Med 1996; 37: 286-289.
7. Del Vecchio S, Ciarmiello A, Potena MI et al. In vivo detection of multidrug-resistant (MDR1) phenotype by techne-tium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24: 150-159.
8. Del Vecchio S, Ciarmiello A, Pace P et al. Fractional retention of technetium-99m sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997; 38: 1348-1351.
9. Ciarmiello A, Del Vecchio S, Silvestro P et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-1683.
10. Barbarics E, Kronauge JF, Cohen D, Davison A, Jones AG, Croop JM. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998; 58: 276-282.
11. Twentyman PR. Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins. Br j Cancer 1988; 57: 254-258.
12. Hyafil F, Vergely C, DuVignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-4602.
13. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-15549.
14. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996; 37: 1578-1582.
15. Ballinger JR, Muzzammil T, Moore MJ. Technetium-99m furifosmin as an agent for functional imaging of multidrug resistance in tumors. J Nucl Med 1997; 38: 1915-1919.
16. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226-4233.
17. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. Comparative study of reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995; 34: 235-241.
18. Colombo T, Gonzalez Paz O, D’Incalci M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996; 73: 866-871.
19. Moretti JL, Azaloux H, Boisseron D, Kouyoumdjian JC, Vilcoq J. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 1996; 23: 980-986.
20. Kostakoglu L, Elahi N, Kiratli P et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 1997; 38: 1003-1008.
21. Koukourakis MI, Koukouraki S, Giatromanolaki A, Skarlatos J, Georgoulias V, Karkavitsas N. Non-small cell lung cancer functional imaging: Increased hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cytotoxic treatment. Clin Cancer Res 1997; 3: 749-754.
22. Derebek E, Kirkali Z, Dogan AS et al. 99Tcm-MIBI scintigraphy in metastatic renal cell carcinoma: Clinical validation of the relationship between 99Tcm-MIBI uptake and P-glycoprotein expression in tumour tissue. Eur J Nucl Med 1996; 23: 976-979.
23. Garcia JR, Kim EE, Wong FCL et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37: 1476-1479.
24. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434^42.
25. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820-823.
26. Ballinger JR, Sheldon KM, Boxen I, Erlichman C, Ling V. Differences between accumulation of 99Tcm-sestamibi and 201Tl-thallous chloride in tumour cells: Role of P-glycoprotein. Quart J Nucl Med 1995; 39: 122-128.
27. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science 1992; 258: 1650-1654.
28. Hendrikse NH, Franssen EJF, van der Graaf WTA et al. 99Tcm-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998; 77: 353-358.
29. Fairchild CR, Moscow JA, O’Brien EE, Cowan KH. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-Tr. Mol Pharmacol 1990; 37: 801-809.
30. Thiebaut F, Tsuruo T, Hamada H, Gottesmann MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistant gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
31. Lum BL, Kaubisch S, Yahanda AM et al. Alteration in eto-poside pharmacokinetics and pharmacodynamics by cyclo-sporine in a Phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
32. Luker GD, Fracasso PM, Dobkin J, Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo. J Nucl Med 1997; 38: 369-372.
33. Chen CC, Meadows B, Regis J et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 1997; 3: 545-552.